KB-1661

Tafasitamab

47720

Background of Tafasitamab

CD19 is a transmembrane glycoprotein specific to B-lineage cells, with expression maintained in over 95% of B-cell malignancies. Tafasitamab, is a humanized monoclonal antibody specifically targeting the CD19 antigen, primarily used in the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It functions as an Fc-enhanced cytolytic antibody, which means it not only directly induces apoptosis in B-cells but also engages immune effector cells to enhance antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) .

Specifications

Catalog Number	KB-1661
Antibody Name	Tafasitamab
Isotype	Human IgG1,kappa
Target	CD19
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	20mM sodium citrate,150mM NaCl, pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma. 2019; 3:310.
Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.